Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05647122 · ClinicalTrials.gov registry record · Phase 1

First in Human Study of AZD9592 in Solid Tumors

A Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
403
Enrollment target
20
Study locations

NCT05647122 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 403 participants, above the 321-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (26% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05647122, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
403 participants
Enrollment target
20
Study locations

Study Summary

This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.

Conditions Studied

Carcinoma, Non-Small Cell Lung Colorectal Neoplasms Head and Neck Neoplasms Advanced Solid Tumours

Interventions

  • DRUG Bevacizumab
  • DRUG Osimertinib
  • DRUG Leucovorin
  • DRUG 5-Fluorouracil (5-FU)
  • DRUG AZD9592

Study Locations (20)

New York

  • Research Site - Mineola
  • Research Site - New York
  • Research Site - New York
  • Research Site - New York

California

  • Research Site - Duarte
  • Research Site - Irvine

Maryland

  • Research Site - Baltimore
  • Research Site - Baltimore

Other

  • Research Site - Kogarah
  • Research Site - Melbourne

Connecticut

  • Research Site - North Haven

District of Columbia

  • Research Site - Washington D.C.

Illinois

  • Research Site - Chicago

Massachusetts

  • Research Site - Milford

Trial Details

FieldValue
Enrollment Target 403 participants
Start Date 2022-12-21
Est. Completion 2027-10-06
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05647122

The ClinicalTrials.gov registry entry for NCT05647122 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 403 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 321-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (26% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.

NCT05647122 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, California, Maryland.

Frequently Asked Questions

What is clinical trial NCT05647122 about?

NCT05647122 is a clinical study titled "First in Human Study of AZD9592 in Solid Tumors". This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and i...

What is the current status of trial NCT05647122?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 403 participants. The study started on 2022-12-21. Estimated completion is 2027-10-06.

What conditions does trial NCT05647122 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Colorectal Neoplasms, Head and Neck Neoplasms, Advanced Solid Tumours.

What interventions are being tested in trial NCT05647122?

The interventions under investigation include: Bevacizumab (DRUG), Osimertinib (DRUG), Leucovorin (DRUG), 5-Fluorouracil (5-FU) (DRUG), AZD9592 (DRUG).

Who is sponsoring clinical trial NCT05647122?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05647122 being conducted?

This trial has 20 study locations across California, Connecticut, District of Columbia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Colorectal Neoplasms

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.